INSIGHT 01Fact
90%
90% of applications are in Pharmaceuticals
805 applications in this field, 768 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsInnovative medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore medicines, formulations and related technologies through publications attributed to selected AstraZeneca legal entities.
≥957docs
80 per month · peak 2025-03 (111)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
90%
805 applications in this field, 768 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
898 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 64 | 75 | 97 | 83 | 62 | 62 | 65 | 63 | 60 | 58 | 57 | 78 |
| Organic fine chemistry | 25 | 25 | 43 | 24 | 30 | 25 | 23 | 22 | 20 | 28 | 16 | 36 |
| Biotechnology | 19 | 22 | 28 | 30 | 15 | 15 | 14 | 26 | 21 | 21 | 12 | 21 |
| Medical technology | 1 | 4 | 9 | 5 | 5 | 2 | 2 | 3 | 2 | 5 | 11 | 4 |
| Analysis of biological materials | 5 | 1 | 4 | 2 | 2 | 4 | 2 | 2 | 3 | 2 | 1 | 5 |
| Handling | 1 | 3 | 4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemical engineering | 2 | 0 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| Measurement | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 4 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 12 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 2 of 2 entities
年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。
Review evidence年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250019666A1
The abstract describes an adenovirus purification workflow intended for scale-up. Claim 1 starts with a sample from a host-cell population at approximately 4×10⁶ cells/mL or higher and combines depth filtration followed by microfiltration, anion-exchange chromatography, then tangential-flow filtration including ultrafiltration and diafiltration. The reading concerns the input conditions and sequence of separation operations.
US20250057764A1
The abstract and claim 1 describe a composition deliverable by a metered-dose inhaler, combining pharmaceutical-grade HFC-152a propellant, active-agent particles and phospholipid particles with perforated microstructures. The active agent is selected from listed drug classes. The reading concerns the propellant and particle combination without inferring adoption by all inhalers or any particular marketed product.
39 publication offices · 957 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Other
Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
ASTRAZENECA AB
BiotechnologyPharmaceuticals
Other
Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie
ASTRAZENECA AB
BiotechnologyPharmaceuticals
Other
Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
ASTRAZENECA AB
Pharmaceuticals
Other
Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
ASTRAZENECA AB
Pharmaceuticals
Other
Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
ASTRAZENECA AB
Analysis of biological materialsMedical technologyBiotechnologyPharmaceuticals
Other
(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
ASTRAZENECA AB
Organic fine chemistryPharmaceuticals
Other
LUC00263I2
ASTRAZENECA AB
Other
Compositions and methods for treating advanced solid tumors
ASTRAZENECA AB
Medical technologyBiotechnologyPharmaceuticals
Other
Methods of treating chronic kidney disease with dapagliflozin
ASTRAZENECA AB
Pharmaceuticals
Other
Type i interferon inhibition in systemic lupus erythematosus
ASTRAZENECA AB
Pharmaceuticals
Invention publication
Londamocitinib for the treatment of asthma
ASTRAZENECA AB
Pharmaceuticals
Invention publication
Treatment of skin disease
ASTRAZENECA AB
BiotechnologyPharmaceuticals
Invention publication
Predicting response to neoadjuvant treatment in non-small cell lung cancer
ASTRAZENECA AB
Biotechnology
Invention publication
Combination therapy for treating cancer
ASTRAZENECA AB
Pharmaceuticals
Invention publication
약제학적 제형
ASTRAZENECA AB
Pharmaceuticals
Invention grant
Methods of delaying pain progression and treating prostate cancer
ASTRAZENECA AB
Pharmaceuticals
Invention publication
심장신장 질환의 치료에 사용하기 위한 sglt2 억제제 및 미네랄코르티코이드 수용체 조절제의 조합
ASTRAZENECA AB
Pharmaceuticals
Other
Methods of treating heart failure with reduced ejection fraction with dapagliflozin
ASTRAZENECA AB
Pharmaceuticals
Other
Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
ASTRAZENECA AB
Pharmaceuticals
Other
Pharmaceutical formulation
ASTRAZENECA AB
Pharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
AstraZeneca AB
Configured aliases: ASTRAZENECA AB
Original review note: 年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。
Review evidenceAstraZeneca UK Limited
Configured aliases: ASTRAZENECA UK LTD
Original review note: 年报第194–195页分别列明 AstraZeneca AB 和 AstraZeneca UK Limited 为100%子公司。两法人独立保留,不自动并入 MedImmune、Alexion 或其他名称变体。
Review evidenceFound a wrong attribution or number? Tell us